The Dawning of a New Day in CKD Anemia Care?
作者信息
Lenihan Colin R, Winkelmayer Wolfgang C
机构信息
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California; and
Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
出版信息
J Am Soc Nephrol. 2016 Apr;27(4):968-70. doi: 10.1681/ASN.2015091009. Epub 2015 Oct 22.
Abstract
摘要
相似文献
1
The Dawning of a New Day in CKD Anemia Care?
J Am Soc Nephrol. 2016 Apr;27(4):968-70. doi: 10.1681/ASN.2015091009. Epub 2015 Oct 22.
2
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Am J Kidney Dis. 2016 Jun;67(6):861-71. doi: 10.1053/j.ajkd.2015.11.021. Epub 2016 Jan 27.
3
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Am J Nephrol. 2017;45(2):127-135. doi: 10.1159/000454818. Epub 2016 Dec 16.
4
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.
Adv Ther. 2018 Jan;35(1):5-11. doi: 10.1007/s12325-017-0655-z. Epub 2017 Dec 28.
5
First-in-class anemia drug takes aim at Amgen's dominion.
Nat Biotechnol. 2013 Nov;31(11):948-9. doi: 10.1038/nbt1113-948b.
6
Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system.
Ren Fail. 2021 Dec;43(1):1170-1171. doi: 10.1080/0886022X.2021.1952881.
7
Deal watch: AstraZeneca bets on FibroGen's anaemia drug.
Nat Rev Drug Discov. 2013 Oct;12(10):730. doi: 10.1038/nrd4135.
8
Emerging treatments for anemia in patients with CKD and ESRD.
Nephrol News Issues. 2017 Apr;31(4):18-22, 24, 26, 29.
9
New Approaches for Anemia in MDS.
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S59-S60. doi: 10.1016/S2152-2650(20)30463-8.
10
Cardiovascular Safety of Roxadustat in CKD Anemia: A Fig Leaf Named Noninferiority.
Clin J Am Soc Nephrol. 2021 Aug;16(8):1155-1157. doi: 10.2215/CJN.08280621.
引用本文的文献
1
Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
J Clin Med. 2022 May 11;11(10):2722. doi: 10.3390/jcm11102722.
2
Efficacy of daprodustat on anemia in hemodialysis patients with sustained inflammation: a case report.
CEN Case Rep. 2022 Nov;11(4):494-498. doi: 10.1007/s13730-022-00706-1. Epub 2022 May 9.
3
Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
Ther Apher Dial. 2021 Dec;25(6):979-987. doi: 10.1111/1744-9987.13686. Epub 2021 May 25.
4
Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Front Pharmacol. 2021 Jan 12;11:573645. doi: 10.3389/fphar.2020.573645. eCollection 2020.
5
Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
Am J Nephrol. 2021;52(1):26-35. doi: 10.1159/000513103. Epub 2021 Feb 9.
6
Biomarkers of iron metabolism in chronic kidney disease.
Int Urol Nephrol. 2021 May;53(5):935-944. doi: 10.1007/s11255-020-02663-z. Epub 2020 Oct 6.
7
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.
Clin Kidney J. 2019 Feb;12(1):129-138. doi: 10.1093/ckj/sfy013. Epub 2018 Mar 9.
8
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Am J Nephrol. 2017;45(5):380-388. doi: 10.1159/000464476. Epub 2017 Mar 25.
9
Remote ischaemic preconditioning: closer to the mechanism?
F1000Res. 2016 Dec 13;5:2846. doi: 10.12688/f1000research.9633.1. eCollection 2016.
本文引用的文献
1
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22.
2
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
J Am Soc Nephrol. 2016 Apr;27(4):1234-44. doi: 10.1681/ASN.2014111139. Epub 2015 Oct 22.
3
Anaemia in kidney disease: harnessing hypoxia responses for therapy.
Nat Rev Nephrol. 2015 Jul;11(7):394-410. doi: 10.1038/nrneph.2015.82. Epub 2015 Jun 9.
4
Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology.
Annu Rev Pathol. 2014;9:47-71. doi: 10.1146/annurev-pathol-012513-104720. Epub 2013 Aug 7.
5
Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes.
Trends Biochem Sci. 2013 Jan;38(1):3-11. doi: 10.1016/j.tibs.2012.10.004. Epub 2012 Nov 28.
6
The VHL/HIF axis in clear cell renal carcinoma.
Semin Cancer Biol. 2013 Feb;23(1):18-25. doi: 10.1016/j.semcancer.2012.06.001. Epub 2012 Jun 13.
7
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 2012 Apr;33(4):207-14. doi: 10.1016/j.tips.2012.01.005. Epub 2012 Mar 6.
8
High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.
Blood. 2011 Jun 9;117(23):e207-17. doi: 10.1182/blood-2010-10-314427. Epub 2011 Mar 29.
9
Hepcidin and iron regulation, 10 years later.
Blood. 2011 Apr 28;117(17):4425-33. doi: 10.1182/blood-2011-01-258467. Epub 2011 Feb 23.
10
Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function.
Gastroenterology. 2010 Dec;139(6):2093-101. doi: 10.1053/j.gastro.2010.06.068. Epub 2010 Jun 30.
Zotero 插件